- $50,000 - $200,000 for one year
| Funding opportunities from the Harvard Institute of Translational Immunology (HITI). | HITI Funding |
The Harvard Institute of Translational Immunology (HITI) and the Leona M. and Harry B. Helmsley Charitable Trust seek innovative applications that will advance our knowledge of type 1 diabetes (T1D), a progressively debilitating autoimmune disease whose sequelae lead to significant morbidity and mortality and whose prevalence has increased dramatically in the past few decades.
This grant program was inspired by the winners of the Harvard Catalyst/InnoCentive Ideation Challenge, "What do we not know about type 1 diabetes." The principal goal of this RFA is to support pilot studies that will lead to sustainable, innovative and, to the extent possible, collaborative projects that will impact the lives of T1D patients.
Projects that address the five research areas identified through the Harvard Catalyst/InnoCentive Ideation Challenge will be given strong preference in the review process:
Click here for more details on these five research areas.
While feasibility will be a key factor in review of submissions, novel approaches are encouraged. Thus, it is recognized that, in some cases, proposals may be limited to proof of principle. Please review the RFA for complete information.
| RFA announcement | November 18, 2010 |
| Applications due | January 26, 2011, 12:00 noon ET |
| Interview invitations | February 25, 2011 |
| Interviews | March 2-4, 2011 |
| Anticipated funding decisions | March 14, 2011 |
| Anticipated project start | March 23, 2011 |
Each proposal PI should insure her/his availability and/or the availability of another senior project member during the scheduled interview dates.